KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Nektar Therapeutics (NKTR) Return on Sales (2016 - 2025)

Nektar Therapeutics has reported Return on Sales over the past 16 years, most recently at 1.59% for Q4 2025.

  • Quarterly results put Return on Sales at 1.59% for Q4 2025, down 184.0% from a year ago — trailing twelve months through Dec 2025 was 2.81% (down 160.0% YoY), and the annual figure for FY2025 was 2.81%, down 160.0%.
  • Return on Sales for Q4 2025 was 1.59% at Nektar Therapeutics, up from 2.97% in the prior quarter.
  • Over the last five years, Return on Sales for NKTR hit a ceiling of 9.75% in Q4 2023 and a floor of 7.37% in Q2 2022.
  • Median Return on Sales over the past 5 years was 2.78% (2022), compared with a mean of 2.78%.
  • Biggest five-year swings in Return on Sales: soared 1233bps in 2023 and later crashed -950bps in 2024.
  • Nektar Therapeutics' Return on Sales stood at 5.87% in 2021, then surged by 56bps to 2.59% in 2022, then soared by 477bps to 9.75% in 2023, then tumbled by -97bps to 0.25% in 2024, then crashed by -740bps to 1.59% in 2025.
  • The last three reported values for Return on Sales were 1.59% (Q4 2025), 2.97% (Q3 2025), and 3.51% (Q2 2025) per Business Quant data.